Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dr. John M. de Castro who wrote (239)	1/29/1998 9:52:00 AM
From: Peter Silsbee	Read Replies (1) of 1494

From the "Personalities" file: Dr. Stuart Lipton appears in a segment on CNN Headline News this week. The segment is about a standard stroke treatment (TPA ??). Lipton says this treatment has a potential side effect which results in neural damage (something to do with glutamate receptors --- sorry, I didn't take notes). In any case, he seems to be making the argument that there should be some sort of neuroprotectant administered in conjunction with the standard treatment. He does not mention any specific compounds, for instance, memantine. PLS P.S. Nice pop this AM, though 50% of nothing is still nothing...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next